Search

Over the past couple of decades, research on the perks of corporate social responsibility has reported that it is a source of competitive advantage and can increase the bottom‐line performance of the organization. However, a somewhat small proportion of this research is focused on the 'greenwash' side, which posits that not all CSR would lead to positive impacts. By extending this line of research, the current study is aimed at investigating the differential impacts of CSR by developing a scale for the three‐dimensional model of CSR attributions coined by Ahmad in 2017, that is, Embedded, P‐Social, and P‐Instrumental CSR, and testing the same with counterproductive sustainability behaviors. The attribution theory was used to explain the relationship between the study variables. Data (N = 311) were collected from the tourism and hospitality sectors. It was found that Embedded and P‐Social CSR practices would be attributed to more genuine CSR and would lead to a reduction in counterproductive sustainability behaviors. Furthermore, the P‐Instrumental CSR would be attributed to more selfish and instrumental practices and hence would be considered as greenwashing, which will consequently lead to enhancing counterproductive sustainability behaviors. The study further tested the mediating role of employees' organizational trust, which was also supported by the results. Several theoretical and practical implications are discussed. [ABSTRACT FROM AUTHOR]

The purpose of this review is to report clinical outcomes of patients undergoing hip arthroscopy for femoroacetabular impingement (FAI) with initial access to the peripheral compartment (PC) of the hip. A search following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed in the PubMed, Embase, and Scopus databases. Studies in which clinical outcomes were reported for patients who underwent hip arthroscopy for FAI with initial access to the PC were included. Data on study characteristics, patient demographics, radiographic outcomes, patient-reported outcomes (PROs), complications, and secondary surgery were extracted. Five studies with 881 patients and 976 hips (55.2% male, age range 32.1 to 48.4 years, follow-up range 3.0 to 74.4 months) were included. In two studies reporting radiographic measurements, the range of preoperative and postoperative alpha angle was 55.5° to 68.7° and 45.5° to 48.3°, respectively. The range of preoperative and postoperative lateral center-edge angles was 33.8° to 39.2° and 30.5° to 32.9°, respectively. Four studies reported one or more PRO measures with all demonstrating significant preoperative to postoperative improvement. The postoperative Non-Arthritic Hip Score (NAHS) and Visual Analog Score (VAS) pain scales ranged from 78.0 to 83.2 and 1.4 to 2.8, respectively. Complication rates ranged from 0.3% to 23.3%, with the rate of paresthesia specifically ranging from 0% to 8.1%. The rate of secondary surgery ranged from 0% to 6.3%. The rate of revision hip arthroscopy and conversion to total hip arthroplasty, specifically, ranged from 0% to 3.1% and 0% to 3.7%, respectively. This systematic review demonstrates that hip arthroscopy for FAI with initial access to the PC shows significant improvements in PROs with low rates of complications and secondary surgery., Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2025, Baig et al.)

Background: Immunotherapy has emerged as a standard treatment for deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Pembrolizumab became widely available as a first-line (1L) option in Australia following the Pharmaceutical Benefits Scheme (PBS) listing in August 2021. The uptake of new treatment options can be lengthy., Methods: The Treatment of Recurrent and Advanced Colorectal Cancer mCRC registry data at participating Australian sites was analysed from January 2015 (when MMR testing became routine). 1L treatment of dMMR cancers was compared with pre- and post-PBS funding., Results: Out of 2819 patients, 2344 (83%) had known MMR status. Of these, 162 (7%) were dMMR, which was associated with older age (median age 69 vs 63 years, P = 0.001), a right-side primary (68% vs 31%, P < 0.001) and a BRAF V600E mutation (49% vs 11%, P < 0.001). Prior to August 2021, 85 out of 117 (73%) patients with dMMR received 1L treatment: 63 out of 85 (74%) chemotherapy and 20 out of 85 (24%) immunotherapy. Following approval, 39 out of 45 (87%) received 1L treatment and 39 out of 39 (100%) pembrolizumab. Of the patients 75 years and older, a significantly higher proportion of patients were treated with any 1L therapy post-PBS listing (89% vs 60%, P = 0.036)., Conclusion: Previously reported associations of dMMR were observed. The higher-than-expected proportion of patients with dMMR is likely driven by the inclusion of older patients in this real-world study. Many patients were able to access immunotherapy prior to PBS listing, potentially through trials or access programs. Early uptake of pembrolizumab following PBS listing has been high, and this effective and well-tolerated option has increased the proportion of elderly patients receiving active therapy., (© 2024 Royal Australasian College of Physicians.)